What are the symptoms and treatment of Kawasaki disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Kawasaki Disease: Symptoms and Treatment

Kawasaki disease is characterized by fever lasting at least 5 days plus four of five principal clinical features: bilateral non-exudative conjunctival injection, oral mucosal changes, polymorphous rash, extremity changes, and cervical lymphadenopathy. 1, 2

Principal Clinical Features

Fever

  • High-spiking fever (typically >102.2°F/39°C, often >104°F/40°C) that persists for an average of 11 days if untreated 2
  • Fever for at least 5 days is required for diagnosis, although experienced clinicians may diagnose with fewer days of fever if other criteria are present 1

Mucosal Changes

  • Erythema and cracking of lips 1
  • Strawberry tongue (erythematous tongue with prominent papillae) 1
  • Diffuse erythema of oral and pharyngeal mucosa 1, 2

Ocular Findings

  • Bilateral bulbar conjunctival injection without exudate 1, 2
  • Sparing of the limbus (area immediately adjacent to the iris) 1
  • Absence of photophobia and eye pain 2

Skin Manifestations

  • Polymorphous rash: maculopapular, diffuse erythroderma, or erythema multiforme-like 1
  • Rash typically appears within 5 days of fever onset 2, 3

Extremity Changes

  • Acute phase: erythema and edema of hands and feet 1, 2
  • Subacute phase: periungual desquamation (peeling around nails) beginning 2-3 weeks after fever onset 1, 2

Lymphadenopathy

  • Cervical lymphadenopathy (≥1.5 cm diameter) 1
  • Usually unilateral and confined to the anterior cervical triangle 1
  • Least common of the principal clinical features 1

Other Clinical Manifestations

Cardiovascular

  • Myocarditis 4
  • Pericarditis 2
  • Coronary artery aneurysms (develop in 15-25% of untreated children) 1

Gastrointestinal

  • Diarrhea, vomiting, abdominal pain 1, 5
  • Hepatitis, jaundice 1
  • Gallbladder hydrops 1, 2
  • Pancreatitis 1, 2

Musculoskeletal

  • Arthritis, arthralgia 1

Diagnosis

Classic Kawasaki Disease

  • Fever for ≥5 days plus ≥4 of the 5 principal clinical features 1, 5
  • In the presence of ≥4 principal features, particularly when hand/foot changes are present, diagnosis can be made with 4 days of fever 1

Incomplete Kawasaki Disease

  • Consider in children with fever ≥5 days and only 2-3 principal clinical features 5
  • More common in infants <6 months who have higher risk of coronary abnormalities 4
  • Diagnosis supported by laboratory findings: elevated ESR, CRP, leukocytosis 5

Treatment Protocol

Initial Treatment

  • Intravenous immunoglobulin (IVIG) 2 g/kg as a single infusion 4
  • High-dose aspirin (80-100 mg/kg/day divided into four doses) until patient is afebrile for at least 48 hours 4
  • Treatment should be initiated within 10 days of fever onset to reduce risk of coronary artery abnormalities 4

Follow-up Treatment

  • After fever resolution, transition to low-dose aspirin (3-5 mg/kg/day) as a single daily dose 4
  • Duration of low-dose aspirin depends on coronary artery status 4

Management of IVIG-Resistant Disease

  • For persistent or recrudescent fever 36 hours after IVIG completion (10-20% of patients) 4
  • Options include second dose of IVIG (2 g/kg), infliximab, or corticosteroids 4

Monitoring and Long-term Management

Cardiac Monitoring

  • Echocardiography to assess for coronary artery abnormalities 4, 5
  • Frequency of monitoring depends on coronary involvement 4
  • Highest risk for coronary thrombosis occurs within first 3 months, peaking at 15-45 days 4

Antiplatelet/Anticoagulation Management

  • For patients with small coronary aneurysms: long-term low-dose aspirin 4
  • For moderate aneurysms (4-6 mm): aspirin plus second antiplatelet agent 4
  • For giant aneurysms (≥8 mm): aspirin plus warfarin or low-molecular-weight heparin 4

Common Pitfalls and Caveats

  • Principal clinical features may not all be present simultaneously; careful history-taking is essential 2, 5
  • Infants and older children/adolescents often have delayed diagnosis and higher risk of coronary abnormalities 5
  • Measles and varicella immunizations should be deferred for 11 months after IVIG administration 4
  • Annual influenza vaccination recommended for children on long-term aspirin therapy 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Kawasaki Disease: Definition, Diagnosis, and Clinical Characteristics

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Diagnosis and management of kawasaki disease.

American family physician, 2015

Guideline

Treatment of Kawasaki Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Diagnosing Kawasaki Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.